All News

Found 2,357 articles

• Cellecta, Inc. Announces Upcoming Presentations At AACR 2017 Annual Meeting

  3/15/2017

• Allergan Pays $90 Million to Get Into CRISPR, Will Have the Option to License Five Programs From Editas Medicine

  3/14/2017

• CRISPR And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc.

  3/14/2017

• Lycera Announces The Appointment Of Pablo J. Cagnoni, M.D., To The Board Of Directors

  3/13/2017

• Third Rock Ventures Quietly Launches Tango Therapeutics in Editas Medicine’s HQ

  3/8/2017

• Abeona Therapeutics Receives Orphan Drug Designation In The European Union For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa

  3/8/2017

• Horizon Discovery Ltd. Enters Into R&D And Licensing Partnership With Amplycell S.A. For Bioproduction Cell Line Optimization

  3/8/2017

• TransOMIC Unveils Transedit-Dual CRISPR Arrayed Library

  3/8/2017

• Precision NanoSystems Unveils Innovative System For Scale-Up Manufacture Of Nanomedicines

  3/8/2017

• The Jackson Laboratory Release: JAX Receives Federal Grant To Improve Crispr-Cas9 Accuracy, Efficiency And Reliability

  3/7/2017

• Applied StemCell, Inc. Announces The Appointment Of Dr. Michele Calos, Stanford Professor And Vice President Of The American Society Of Gene And Cell Therapy To Its Scientific Advisory Board (SAB)

  3/6/2017

• CRISPR/Cas9 Startup Exonics Therapeutics Launches in Boston

  2/28/2017

• European Patent Office To Grant CRISPR-Cpf1 Patent To Broad Institute, MIT, And Harvard

  2/28/2017

• CRISPR Announces The Appointment Of Jon Terrett, Ph.D. To Head Of Immuno-Oncology Research And Translation

  2/28/2017

• Vycellix And H. Lee Moffitt Cancer Center & Research Institute Announce A Collaborative Research Study To Evaluate Novel Product Candidates For Improving Adoptive Cell Immunotherapies For Cancer

  2/27/2017

• Future Biotech Giants: 11 Life Science Entrepreneurs Under 30

  2/24/2017

• ToolGen Highlights Study Results Demonstrating Utility Of AAV-Compatible Cas9 System In Vivo Genome Editing

  2/22/2017

• Synthego Release: Survey: Over 80 Percent Of New CRISPR Users Are Conducting Gene Editing For The First Time

  2/20/2017

• Abeona Therapeutics Provides Update From ABO-102 Phase I/II MPS IIIA Clinical Trial At The 13th Annual WORLDSymposium 2017

  2/17/2017

• This is Why the Decision on Who Invented CRISPR Matters

  2/16/2017